[
  {
    "ts": null,
    "headline": "Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes",
    "summary": "Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD). The stock is trading lower as data did not meet investor expectations. STAT News reported that Axpaxli's durability advantage over the active control was smaller than investors had anticipated, potentially raising questions about its commercial outlook in wet age-related macular degeneration",
    "url": "https://finnhub.io/api/news?id=86dbe91cfb7542af7a0f4b4ca10f97ef78c61ae2093bb311bacf9750bdf82289",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771542067,
      "headline": "Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes",
      "id": 139152835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD). The stock is trading lower as data did not meet investor expectations. STAT News reported that Axpaxli's durability advantage over the active control was smaller than investors had anticipated, potentially raising questions about its commercial outlook in wet age-related macular degeneration",
      "url": "https://finnhub.io/api/news?id=86dbe91cfb7542af7a0f4b4ca10f97ef78c61ae2093bb311bacf9750bdf82289"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts […]",
    "url": "https://finnhub.io/api/news?id=625dc38027fe307d7814fb1ad7badda93dc8d4eb46ad0c3fea04fa2c5e8ab6ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512820,
      "headline": "Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)",
      "id": 139149176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts […]",
      "url": "https://finnhub.io/api/news?id=625dc38027fe307d7814fb1ad7badda93dc8d4eb46ad0c3fea04fa2c5e8ab6ca"
    }
  },
  {
    "ts": null,
    "headline": "AtaiBeckley names Michael Faerm as finance chief",
    "summary": "AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...",
    "url": "https://finnhub.io/api/news?id=52d641e2e8db02ea8f8cdd82e137be0a44b7b4d316a029f4d8f30d35363802d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771507260,
      "headline": "AtaiBeckley names Michael Faerm as finance chief",
      "id": 139146195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...",
      "url": "https://finnhub.io/api/news?id=52d641e2e8db02ea8f8cdd82e137be0a44b7b4d316a029f4d8f30d35363802d1"
    }
  },
  {
    "ts": null,
    "headline": "Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",
    "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adminis",
    "url": "https://finnhub.io/api/news?id=43abca8a68752187508086ea575579de09a22acc47ee1886c2185b3d03514531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771502400,
      "headline": "Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",
      "id": 139146380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adminis",
      "url": "https://finnhub.io/api/news?id=43abca8a68752187508086ea575579de09a22acc47ee1886c2185b3d03514531"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts Regeneron's Garetosmab BLA For Priority Review For Treatment Of Adults With Fibrodysplasia Ossificans Progressiva",
    "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab",
    "url": "https://finnhub.io/api/news?id=3a17e0e1264048fc4eac1581eca2f4d1bfc4799532a2b189571b629da8b7c0e7",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771488690,
      "headline": "FDA Accepts Regeneron's Garetosmab BLA For Priority Review For Treatment Of Adults With Fibrodysplasia Ossificans Progressiva",
      "id": 139148352,
      "image": "",
      "related": "REGN",
      "source": "Benzinga",
      "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab",
      "url": "https://finnhub.io/api/news?id=3a17e0e1264048fc4eac1581eca2f4d1bfc4799532a2b189571b629da8b7c0e7"
    }
  }
]